Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jul;79(1):62-75.
doi: 10.1002/jpn3.12221. Epub 2024 May 2.

Biomarkers predicting the effect of anti-TNF treatment in paediatric and adult inflammatory bowel disease

Dwight A Winter  1 , Pauline de Bruyne  2 , Janneke van der Woude  3 , Dimitris Rizopoulos  4 , Lissy de Ridder  1 , Janneke Samsom  5 , Johanna C Escher  1
Affiliations
Observational Study

Biomarkers predicting the effect of anti-TNF treatment in paediatric and adult inflammatory bowel disease

Dwight A Winter et al. J Pediatr Gastroenterol Nutr. 2024 Jul.

Abstract

Objectives: Paediatric and adult inflammatory bowel disease (pIBD, aIBD) patients may lose response to anti-tumour necrosis factor (TNF) treatment within the first year. Adult-extrapolated weight-based dosing is incorrect in children, due to age-related pharmacokinetic differences. We investigated biomarkers for initial and maintenance of response to infliximab (IFX) or adalimumab (ADA), comparing pIBD and aIBD patients.

Methods: In this prospective, observational study, pIBD (n = 24) and aIBD (n = 21) patients were included when initiating anti-TNF. Escalation from standard dosing and continued anti-TNF at 12 and 18 months were assessed. Biomarkers included clinical laboratory parameters, faecal calprotectin (FCP) and IFX trough levels (TLs). Plasma proteomics was performed in pIBD.

Results: During our study, treatment escalation (in clinical loss of response) occurred more common in pIBD versus aIBD (p = 0.02). We established that IFX therapy escalation in pIBD patients was not due to low infliximab levels. We identified 9 pro-inflammatory proteins that were elevated in patients losing response.

Conclusion: Anti-TNF exposure-response relationship may be different in pIBD versus aIBD. No biomarkers for maintained response were identified, but 9 inflammatory proteins were of interest as potential predictors for loss of response in pIBD.

Keywords: IBD; infliximab; pharmacodynamics; pharmacokinetics.

PubMed Disclaimer

References

REFERENCES

    1. Ben‐Horin S, Chowers Y. Tailoring anti‐TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11:243‐255. doi:10.1038/nrgastro.2013.253
    1. Bermejo F, Guerra I. Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol. 2014;7:359‐367. doi:10.2147/CEG.S45297
    1. Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half‐life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20:2247‐2259.
    1. Winter DA, Joosse ME, de Wildt SN, Taminiau J, de Ridder L, Escher JC. Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations. J Pediatr Gastroenterol Nutr. 2020;70:763‐776. doi:10.1097/MPG.0000000000002631
    1. Clarkston K, Tsai YT, Jackson K, Rosen MJ, Denson LA, Minar P. Development of infliximab target concentrations during induction in pediatric crohn disease patients. J Pediatr Gastroenterol Nutr. 2019;69:68‐74. doi:10.1097/MPG.0000000000002304

Publication types

LinkOut - more resources